WELLESLEY, Mass.–Eli Lilly and Company has reached an agreement to acquire Calytrix Bio, a Massachusetts biotechnology company developing experimental treatments for rare blood cancers, in a transaction valued at up to $1.5 billion.
The acquisition will expand Lilly’s presence in the treatment of myeloproliferative neoplasms, a group of blood cancers characterized by the abnormal production of blood cells.
Under the agreement, Calytrix shareholders could receive up to $1.5 billion in cash, including an upfront payment and additional payments tied to the achievement of clinical and regulatory milestones.
The companies did not disclose the amount of the initial payment or provide a timeline for completing the transaction.
Founded in 2025, Calytrix is developing precision medicines targeting genetic mutations associated with essential thrombocythemia and myelofibrosis, two forms of myeloproliferative neoplasms.
Essential thrombocythemia causes the bone marrow to produce excessive platelets, increasing the risk of blood clots and bleeding complications. Myelofibrosis involves scarring of the bone marrow, which interferes with normal blood cell production and can lead to anemia, fatigue and other serious complications.
Calytrix’s lead investigational treatment is a biparatopic antibody designed to target mutant calreticulin, or mCALR, a protein associated with the development of certain blood cancers.
The experimental therapy is intended to recognize and target multiple forms of the mutated protein while minimizing damage to healthy cells.
Unlike treatments that primarily control symptoms or reduce complications, Calytrix is developing its antibody to address the underlying biological mechanisms responsible for disease progression.
The company believes targeting mutant calreticulin could help eliminate abnormal blood cell populations while preserving healthy blood cell production.
The treatment remains in preclinical development and has not yet been evaluated in human clinical trials.
Brad Prosek, President and CEO of Calytrix Bio, said the acquisition could accelerate the development of the company’s lead program.
“Calytrix was founded on the belief that patients with MPNs deserve therapies that do more than manage symptoms,” said Prosek. “From the beginning, our goal has been to alter the disease course in mCALR-driven ET and MF. This transaction represents an important step toward accelerating that vision. We look forward to Lilly advancing the program through the clinic and exploring its potential to benefit patients across the disease spectrum. I am deeply grateful to our team, scientific advisors, and committed investors, each of whom has supported delivery of Calytrix’s program to the starting line for clinical development.”
The acquisition builds on Lilly’s existing capabilities in blood cancer research and development while adding a potential treatment targeting the genetic drivers of essential thrombocythemia and myelofibrosis.
Calytrix was established by J.P. Morgan Life Sciences Private Capital, the life sciences venture capital division of J.P. Morgan Asset Management.
The company initially raised Series A financing co-led by J.P. Morgan Life Sciences Private Capital and Westlake BioPartners.
It subsequently secured Series B financing led by Avoro Ventures to support the advancement of its therapeutic development program.
Centerview Partners is serving as the exclusive financial advisor to Calytrix, while Goodwin Procter is providing legal counsel.
Paul, Weiss, Rifkind, Wharton & Garrison is serving as legal counsel to Lilly.
The proposed acquisition would give Lilly control of Calytrix’s preclinical antibody program as the pharmaceutical company seeks to expand its portfolio of precision treatments for blood cancers.


